Ann Arbor, MI, United States of America

Noah Nelson

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: University of Kansas, University of Michigan. Active years: 2021-2025.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Inventor Noah Nelson

Introduction

Noah Nelson is an accomplished inventor based in Ann Arbor, MI (US). He has made significant contributions to the field of therapeutic nanoparticles, focusing on enhancing bone repair. With a total of 2 patents, his work is paving the way for advancements in medical treatments.

Latest Patents

One of Noah Nelson's latest patents is titled "Devices, compositions and related methods for accelerating and enhancing bone repair." This invention relates to novel therapeutic nanoparticles that are associated with angiogenesis-activating agents. The patent outlines methods of synthesizing these nanoparticles, as well as systems and methods for utilizing them in therapeutic settings to enhance and activate angiogenesis at targeted tissue regions.

Career Highlights

Throughout his career, Noah has worked with prestigious institutions such as the University of Kansas and the University of Michigan. His research has focused on innovative solutions that address critical medical challenges, particularly in the area of bone repair.

Collaborations

Noah has collaborated with notable individuals in his field, including Mark S Cohen and Laird Forrest. These partnerships have contributed to the development of his groundbreaking inventions.

Conclusion

Noah Nelson's work in the field of therapeutic nanoparticles represents a significant advancement in medical technology. His innovative patents and collaborations highlight his commitment to improving healthcare solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…